Palifermin (keratinocyte growth factor, KGF) is the prototype of an anti-mucositis drug and was first shown to reduce the duration and severity of oral mucositis after intensive chemotherapy and radiotherapy for hematologic cancers [101]. This evidence concerns the gene FGF7 and mucositis.